First-Line Immune Checkpoint Inhibitors Underused in Metastatic Melanoma
Source: Cancer Therapy Advisor, August 2022
First-line immune checkpoint inhibitors have improved survival in patients with metastatic melanoma but remain underused in this population, according to research published in JAMA Network Open.
The study showed that first-line immune checkpoint inhibitor use increased from 2010 to 2019, but 38% of patients were not receiving first-line immune checkpoint inhibitors in 2019.
The study included 16,831 adults 20 years of age and older who were newly diagnosed with stage IV cutaneous melanoma from 2010 to 2019. The vast majority of patients were non-Hispanic White (93.6%), and most were men (67.9%).